- Previous Close
478.30 - Open
475.55 - Bid --
- Ask --
- Day's Range
468.85 - 497.40 - 52 Week Range
308.00 - 571.00 - Volume
293,457 - Avg. Volume
521,029 - Market Cap (intraday)
53.418B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
38.50 - EPS (TTM)
12.40 - Earnings Date Nov 9, 2024
- Forward Dividend & Yield 5.10 (1.08%)
- Ex-Dividend Date Jul 18, 2024
- 1y Target Est
333.00
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
www.advancedenzymes.com323
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: ADVENZYMES.NS
View MorePerformance Overview: ADVENZYMES.NS
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADVENZYMES.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADVENZYMES.NS
View MoreValuation Measures
Market Cap
52.94B
Enterprise Value
47.93B
Trailing P/E
38.19
Forward P/E
33.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.40
Price/Book (mrq)
4.00
Enterprise Value/Revenue
7.60
Enterprise Value/EBITDA
20.53
Financial Highlights
Profitability and Income Statement
Profit Margin
21.97%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6.31B
Net Income Avi to Common (ttm)
1.39B
Diluted EPS (ttm)
12.40
Balance Sheet and Cash Flow
Total Cash (mrq)
5.29B
Total Debt/Equity (mrq)
3.45%
Levered Free Cash Flow (ttm)
--
Research Analysis: ADVENZYMES.NS
View MoreCompany Insights: ADVENZYMES.NS
ADVENZYMES.NS does not have Company Insights